foxo4 dri peptide senolytic 2023 study Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4 D-Retro-Inverso(DRI) peptide
FOXO4 D Retro Inverso(DRI) peptide The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI Wikipedia
Pay in 4 interest-free payments of $7.07 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


